estrogen receptor-negative breast cancer
Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:0060076
Name estrogen receptor-negative breast cancer
Definition A hormone receptor-negative breast cancer that is characterized by the absence of estrogen receptors.
Source DiseaseOntology.org
Alt Ids
Xrefs
Path disease disease of cellular proliferation cancer organ system cancer breast cancer hormone receptor-negative breast cancer estrogen receptor-negative breast cancer

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR2 amp Brivanib estrogen receptor-negative breast cancer no benefit detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01471106 Phase II Dasatinib Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer Completed USA 0
NCT01937117 Phase II Pertuzumab + Trastuzumab Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer Active, not recruiting USA 0
NCT04020185 Phase Ib/II IMSA101 + unspecified PD-L1 antibody IMSA101 + unspecified PD-1 antibody IMSA101 Safety and Efficacy Study of IMSA101 in Refractory Malignancies Completed USA 0